Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan · Delayed Price · Currency is TWD 125.00
-2.00 (-1.57%)
Nov 21, 2025, 2:38 PM CST
TPE:6919 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| 34.99 | 44.43 | 38.93 | 12.82 | 12.34 | 10.35 | Upgrade | |
Revenue Growth (YoY) | -29.99% | 14.13% | 203.68% | 3.90% | 19.22% | -44.50% | Upgrade |
Cost of Revenue | 10.63 | 13.67 | 11.46 | 3.21 | 3.11 | 3.68 | Upgrade |
Gross Profit | 24.36 | 30.76 | 27.47 | 9.61 | 9.23 | 6.68 | Upgrade |
Selling, General & Admin | 92.48 | 97.79 | 36.95 | 34.21 | 59.35 | 23.29 | Upgrade |
Research & Development | 646.93 | 650.12 | 503.99 | 295.02 | 180.62 | 88.98 | Upgrade |
Operating Expenses | 739.41 | 747.91 | 540.94 | 329.23 | 239.97 | 112.28 | Upgrade |
Operating Income | -715.05 | -717.14 | -513.47 | -319.62 | -230.73 | -105.6 | Upgrade |
Interest Expense | -0.2 | -0.33 | -0.5 | -0.67 | -2.9 | -4.51 | Upgrade |
Interest & Investment Income | 191.87 | 74.21 | 17.42 | 5.19 | 0.1 | 0.04 | Upgrade |
Currency Exchange Gain (Loss) | 33.63 | 38.63 | -1.03 | 14.23 | -1.07 | 5.87 | Upgrade |
Other Non Operating Income (Expenses) | 1.51 | 15.81 | 9.12 | 14.83 | 10.34 | 5.81 | Upgrade |
EBT Excluding Unusual Items | -488.25 | -588.83 | -488.46 | -286.05 | -224.26 | -98.4 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | -0.11 | - | - | Upgrade |
Pretax Income | -488.25 | -588.83 | -488.46 | -286.16 | -224.26 | -98.4 | Upgrade |
Income Tax Expense | - | - | - | - | 0.03 | 0.09 | Upgrade |
Net Income | -488.25 | -588.83 | -488.46 | -286.16 | -224.29 | -98.49 | Upgrade |
Net Income to Common | -488.25 | -588.83 | -488.46 | -286.16 | -224.29 | -98.49 | Upgrade |
Shares Outstanding (Basic) | 1,540 | 1,430 | 1,239 | 1,171 | 920 | 745 | Upgrade |
Shares Outstanding (Diluted) | 1,540 | 1,430 | 1,239 | 1,171 | 920 | 745 | Upgrade |
Shares Change (YoY) | 13.14% | 15.40% | 5.77% | 27.35% | 23.49% | 6.52% | Upgrade |
EPS (Basic) | -0.32 | -0.41 | -0.39 | -0.24 | -0.24 | -0.13 | Upgrade |
EPS (Diluted) | -0.32 | -0.41 | -0.39 | -0.24 | -0.24 | -0.13 | Upgrade |
Free Cash Flow | -419.82 | -532.31 | -432.54 | -256.93 | -125.6 | -49.55 | Upgrade |
Free Cash Flow Per Share | -0.27 | -0.37 | -0.35 | -0.22 | -0.14 | -0.07 | Upgrade |
Gross Margin | 69.62% | 69.23% | 70.56% | 74.94% | 74.83% | 64.49% | Upgrade |
Operating Margin | -2043.58% | -1613.95% | -1318.88% | -2493.17% | -1869.95% | -1020.30% | Upgrade |
Profit Margin | -1395.39% | -1325.18% | -1254.64% | -2232.10% | -1817.76% | -951.56% | Upgrade |
Free Cash Flow Margin | -1199.83% | -1197.97% | -1111.01% | -2004.12% | -1017.90% | -478.70% | Upgrade |
EBITDA | -692.84 | -695.71 | -493.68 | -302.36 | -214.49 | -94.43 | Upgrade |
D&A For EBITDA | 22.21 | 21.43 | 19.79 | 17.26 | 16.24 | 11.17 | Upgrade |
EBIT | -715.05 | -717.14 | -513.47 | -319.62 | -230.73 | -105.6 | Upgrade |
Advertising Expenses | - | - | 0.06 | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.